As clinical trials become increasingly decentralized and operationally complex, sponsors are relying on a growing network of third party vendors to support execution of the clinical trial protocol. Contract research organizations (CROs), central laboratories, home nursing vendors, logistics companies, and patient recruitment firms are now routinely playing a role in clinical trials. While this model can improve efficiency and patient access, it can also create significant products liability if responsibilities are not defined clearly and managed appropriately.
Many sponsors assume that outsourcing trial functions also transfers the associated products liability exposure. In reality,
plaintiffs frequently name multiple parties in litigation following an adverse event, and sponsors often remain the primary target regardless of which vendor performed the underlying activity. Operational fragmentation can also create gaps in oversight, inconsistent documentation practices, unclear reporting obligations, and confusion regarding responsibility for trial related activities. These issues can become particularly problematic when litigation arises following a serious injury.
One area of growing concern involves the delegation of patient facing trial activities to third party vendors. Home health vendors, for example, may administer investigational products, collect biological samples, or monitor patients remotely outside of traditional clinical settings. While decentralized trial models can improve enrollment and retention, they may also reduce the sponsor’s visibility into how the protocol is being implemented. Inconsistent training, documentation deficiencies, or communication failures between vendors and sites can create significant liability exposure if a patient suffers harm and questions later arise regarding whether the protocol was designed properly.
Similarly, logistics and supply chain vendors can introduce additional risk into the clinical trial process. Investigational products may require strict temperature controls, chain of custody documentation, or specialized packaging. Vendor errors could potentially compromise product integrity and lead to patient injury.
Contractual allocation of responsibilities is therefore critical in decentralized and vendor supported clinical trials. Sponsors should carefully evaluate how agreements address indemnification obligations, insurance requirements, adverse event reporting timelines, protocol compliance responsibilities, audit rights, and quality expectations. Vague contractual language can create significant complications after an adverse event occurs, particularly when multiple vendors are involved in overlapping trial functions.
As clinical trial models continue to evolve, decentralized trials will likely remain an important part of the life sciences industry. However, operational convenience should not obscure the potential liability implications associated with fragmented trial ecosystems. From a risk management perspective, sponsors should recognize that outsourcing operational functions does not eliminate accountability. In many cases, the complexity created by multiple vendors can increase the likelihood of communication failures, documentation gaps, and unclear responsibility during high pressure situations. Careful planning, robust vendor management practices, and clearly defined contractual obligations remain critical components of reducing exposure in modern clinical trial operations.